Clinical Trial Update: Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant camrelizumab combined with chemotherapy in triple negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Aiping Shi | Conditions: Triple Negative Breast Cancer (TNBC) | Phase 2 | Status: UNKNOWN